icon-    folder.gif   Conference Reports for NATAP  
 
  IAS 2013: 7th IAS Conference on HIV
Pathogenesis Treatment and Prevention
June 30 - July 3 2013
Kuala Lumpur, Malaysia
Back grey_arrow_rt.gif
 
 
 
Etravirine 200mg twice daily combined with atazanavir/ritonavir 300/100mg or 400/100mg once daily in treatment-experienced patients: primary 48-week efficacy and safety analysis of the TEACH trial
 
 
  Reported by Jules Levin
IAS 2013 June 30-July 3 Kuala Lumpur
 
Catherine Orrell,1 Franco Felizarta,2 André Nell,3 Thomas N Kakuda,4 Ludo Lavreys,5 Steven Nijs,5 Lotke Tambuyzer,5 Rodica Van Solingen-Ristea,4 Frank L Tomaka4
1Desmond Tutu HIV Foundation, UCT Medical School, Cape Town, South Africa; 2Private Practice, Bakersfield, CA, USA; 3Farmovs Parexel, Bloemfontein, South Africa; 4Janssen Research & Development LLC, Titusville, NJ, USA; 5Janssen Infectious Diseases BVBA, Beerse, Belgium

IAS1.gif

IAS2.gif

IAS3.gif

IAS4.gif

IAS5.gif

IAS6.gif

IAS7.gif

IAS8.gif

IAS9.gif